Barclays PLC Sells 2,548 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Barclays PLC lowered its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 4.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 56,540 shares of the company’s stock after selling 2,548 shares during the quarter. Barclays PLC owned 0.20% of Krystal Biotech worth $10,290,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in KRYS. Blue Trust Inc. raised its holdings in Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after buying an additional 163 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Krystal Biotech by 11.1% during the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after purchasing an additional 94 shares during the period. Louisiana State Employees Retirement System bought a new stake in shares of Krystal Biotech in the second quarter worth about $2,296,000. EFG Asset Management North America Corp. increased its holdings in Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after purchasing an additional 60 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Krystal Biotech by 115.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock valued at $35,583,000 after purchasing an additional 103,928 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

KRYS has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Tuesday, December 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Stifel Nicolaus lifted their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Finally, Chardan Capital reissued a “buy” rating and issued a $212.00 price target on shares of Krystal Biotech in a research note on Thursday, December 12th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $206.67.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.10% of the stock is owned by insiders.

Krystal Biotech Trading Up 2.4 %

Shares of NASDAQ:KRYS opened at $167.61 on Tuesday. Krystal Biotech, Inc. has a 12-month low of $107.50 and a 12-month high of $219.34. The stock has a market capitalization of $4.82 billion, a price-to-earnings ratio of 94.69 and a beta of 0.80. The stock has a fifty day simple moving average of $181.13 and a two-hundred day simple moving average of $185.30.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. The company had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s revenue for the quarter was up 879.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.67) EPS. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).